| Identification | Back Directory | [Name]
(1R,5S,6S)-6-[1(R)-Hydroxyethyl]-1-methyl-2-[1-(2-thiazolin-2-yl)azetidin-3-ylsulfanyl]-1-carba-2-penem-3-carboxylic acid pivaloyloxymethyl ester | [CAS]
161715-24-8 | [Synonyms]
ME1211
TBPM-PI
SPR-994
OrapeneM
TebipeneM pivoxi
Taibipeinan ester
Tebipenem Pivoxil
Tebipenem Pivoxil-d4
Tebipenem pivoxil(L-084)
TEBIPENEM PIVOXIL USP/EP/BP
(1R,5S,6S)-6-[1(R)-Hydroxyethyl]-1-methyl-2-[1-(2-thiazolin-2-yl)azetidin-3-ylsulfanyl]-1-carba-2-penem-3-carboxylic acid pivaloyloxymethyl ester
(4R,5S,6S)-pivaloyloxymethyl 3-(1-(4,5-dihydrothiazol-2-yl)azetidin-3-ylthio)-6-((R)-1-hydroxyethyl)-4-methyl-7-oxo-1-aza-bicyclo[3.2.0]hept-2-ene-2-carboxylate
[(2,2-Dimethylpropanoyl)oxy]methyl (4R,5S,6S)-3-{[1-(4,5-dihydro-1,3-thiazol-2-yl)azetidin-3-yl]sulfanyl}-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
(4R,5S,6S)-3-[[1-(4,5-Dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-Methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid (2,2-DiMethyl-1-oxopropoxy)Methyl Ester
1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylicacid,3-[[1-(4,5-dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-[(1R)-1-hydroxyethyl]-4-Methyl-7-oxo-,(2,2-diMethyl-1-oxopropoxy)Methyl ester, (4R,5S,6S)-
[4R-[4α,5β,6β(R*)]]-3-[[1-(4,5-Dihydro-2-thiazolyl)-3-azetidinyl]thio]-6-(1-hydroxyethyl)-4-Methyl-7-oxo-1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic Acid (2,2-DiMethyl-1-oxopropoxy)Methyl Ester | [EINECS(EC#)]
1308068-626-2 | [Molecular Formula]
C23H32N2O6S2 | [MDL Number]
MFCD17215369 | [MOL File]
161715-24-8.mol | [Molecular Weight]
496.64 |
| Chemical Properties | Back Directory | [Melting point ]
140-142℃ | [Boiling point ]
661.9±65.0 °C(Predicted) | [density ]
1.50 | [storage temp. ]
Sealed in dry,Store in freezer, under -20°C | [solubility ]
Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly) | [form ]
Solid | [pka]
14.36±0.20(Predicted) | [color ]
White | [InChIKey]
SNUDIPVBUUXCDG-QHSBEEBCSA-N | [SMILES]
N12[C@@]([H])([C@@H]([C@H](O)C)C1=O)[C@@H](C)C(SC1CN(C3=NCCS3)C1)=C2C(OCOC(=O)C(C)(C)C)=O |
| Hazard Information | Back Directory | [Chemical Properties]
White Solid | [Uses]
Tebipenem Pivoxil is an oral carbapenem antibiotic. Tebipenem Pivoxil is absorbed and metabolized into Tebipenem, its active metabolite which showed excellent bactericidal activity against β-lactamase
-nonproducing, ampicillin-resistant isolates. | [Uses]
Tebipenem pivoxil(L-084) is a novel oral carbapenem antibiotic with an IC50 of 100 μg/ml for human CYP isoforms. In mouse, rat, dog and monkey, TBPM-PI were absorbed quickly, and the bioavailability was (71.4, 59.1, 34.8 and 44.9%, respectively. There was | [Definition]
ChEBI: Tebipenem pivoxil is a member of carbapenems and a pivaloyloxymethyl ester. | [Biological Activity]
Tebipenem pivoxil (L-084I; ME1211; SPR994; Tebi-pivoxil; TBM-PI) corresponds to the orally bioavailable pivalyl ester prodrug form of the carbapenem class broad-spectrum β-lactam antibiotic Tebipenem (LJC 11,036; SPR859; TBM). TBM is potent against both gram-positive and gram-negative bacteriaincluding penicillin-resistant S. pneumoniae (PRSP) and many β-lactamase-producing strainswhile being less effective against methicillin-resistant S. aureus (MRSA)S. marcescensand P. aeruginosa. TBM is 2- to 64-fold more potent than imipenemcefdinirand faropenem against clinical isolates from respiratory and urinary-tract infections. | [in vivo]
Tebipenem pivoxil (L084) (0-4.00 g/kg; p.o.; once) shows minimal lethal dosage (MLD) of 4.00 g/kg and the maximum tolerance dosage (MTD) of 3.40 g/kg in mice[1].
Tebipenem pivoxil (50 and 100 mg/kg; p.o.; once) significantly protects the sepsis mice challenged with various pathogenic bacteria[1]. | Animal Model: | KM mice weighing 18–22 g[1] | | Dosage: | 2.89, 3.40 and 4.00 g/kg | | Administration: | Oral administration (tablet), once | | Result: | Within the 14-day observation period, only one mouse was dead in the maximum oral dosage (4.00 g/kg). The minimal lethal dosage (MLD) was 4.00 g/kg and the maximum tolerance dosage (MTD) in the mice was 3.40 g/kg. Showed dose-dependent liver and kidney damage. |
| Animal Model: | ICR mice, sepsis mouse models[1] | | Dosage: | 50 and 100 mg/kg | | Administration: | Oral administration (tablet), once | | Result: | Significantly increased the survival number of the sepsis mice within a 168 h observation period. |
| [IC 50]
β-lactam |
|
|